forstoringsglas

Vinge advises Xspray Pharma in connection with a directed share issue

Vinge has advised the pharmaceutical development company Xspray Pharma in connection with a directed share issue, whereby Xspray receives proceeds of approximately SEK 122 million.
December 10, 2019

Vinge advices EQT VIII in connection with the acquisition of Recover Nordic

Vinge has adviced EQT VIII in connection with the acquisition of Recover Nordic from funds advised by Agilitas Private Equity.
December 10, 2019

Vinge advised Nordea and Citigroup on directed share issue in Better Collective

Vinge advised Nordea Bank Abp and Citigroup Global Markets Limited which are acting as Global Coordinators and Bookrunners in connection with a directed share issue of SEK 312 million in Better Collective A/S through an accelerated book building procedure.
December 04, 2019

Vinge advises Opus in connection with the takeover bid from Ograi

Ograi BidCo AB has announced a public offer to the shareholders of Opus Group AB (publ) to tender all their shares in Opus to Ograi.
December 02, 2019

Vinge advised Trianon on directed share issue

Vinge advised Fastighets AB Trianon in connection with a directed share issue of SEK 210 million through an accelerated book building procedure.
December 02, 2019

Vinge advised Lifco on MTN program

Vinge has advised Lifco AB in connection with its establishment of an MTN program with a framework amount of SEK 3 billion.
December 02, 2019

Vinge advises Vostok New Ventures Ltd in connection with an investment in Voi

Vinge has assisted Vostok New Ventures Ltd (“Vostok”) in connection with an investment by a number of investors of in total USD 85 million in Voi Technology AB, a company that provides an electric scooter sharing service.
November 29, 2019

Vinge advises Gränges in conjunction with acquisition of Aluminium Konin

Vinge has advised Gränges AB (publ) in connection with the acquisition of Aluminium Konin, a Polish aluminium manufacturer, for SEK 2.3 billion from Boryszew Group. In connection with the transaction, Gränges intends to perform a rights issue for SEK 2 billion. In order to finance the acquisition, Gränges has entered into a bridge financing facility agreement with certain Nordic banks for SEK 2.3 billion.
November 28, 2019

Vinge has advised Nextmune and Spectrum Veterinary in connection with acquisition of operations from ALK

Vinge has advised Nextmune and its U.S. subsidiary Spectrum Veterinary, LLC, in connection with the acquisition of U.S. veterinary allergy testing and treatment activities from ALK.
November 28, 2019

Vinge assists Lantmännen in connection with issue of subordinated debentures

Lantmännen co operative association has published a prospectus in relation to an offer to subscribe for subordinated debentures.
November 22, 2019

Vinge represented sellers when Polhem acquired shares in Solör

Vinge represented the sellers Meritor, Inc. Retirement Plan, Sunrise BE I, LLC and YRC Worldwide, Inc. Master Pension Plans Trust in their divestment of shares in Solör Bioenergi Holding AB (”Solör”) to Polhem Infra KB (”Polhem”).
November 21, 2019

Vinge advises SBB on its offer for Hemfosa

Samhällsbyggnadsbolaget i Norden AB (publ) (“SBB”) has announced a recommended public offer to the shareholders of Hemfosa Fastigheter AB (publ) (“Hemfosa”) to tender all their shares in Hemfosa to SBB.
November 15, 2019

Vinge advises property company Hembla in connection with Vonovia’s mandatory cash offer

On 7 November 2019, Vonovia SE announced, through its indirectly wholly-owned subsidiary HomeStar InvestCo AB, a mandatory cash offer to the shareholders of Hembla AB (publ) to acquire all shares in Hembla.
November 15, 2019

Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 900 million

Vinge has advised Skandinaviska Enskilda Banken AB (publ) as to Swedish law in connection with the issuance of Additional Tier 1 Capital (AT1) of USD 900 million to optimise its capital structure.
November 14, 2019

Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.
November 13, 2019
Next